Author:
Koneswarakantha Björn,Ménard Timothé,Rolo Donato,Barmaz Yves,Bowling Rich
Abstract
Abstract
Background
The increasing number of clinical trials and their complexity make it challenging to detect and identify clinical quality issues timely. Despite extensive sponsor audit programs and monitoring activities, issues related to data integrity, safety, sponsor oversight and patient consent have recurring audit and inspection findings. Recent developments in data management and IT systems allow statistical modeling to provide insights to clinical Quality Assurance (QA) professionals to help mitigate some of the key clinical quality issues more holistically and efficiently.
Methods
We used findings from a curated data set from Roche/Genentech operational and quality assurance study data, covering a span of 8 years (2011–2018) and grouped them into 5 clinical impact factor categories, for which we modeled the risk with a logistic regression using hand crafted features.
Results
We were able to train 5 interpretable, cross-validated models with several distinguished risk factors, many of which confirmed field observations of our quality professionals. Our models were able to reliably predict a decrease in risk by 12–44%, with 2–8 coefficients each, despite a low signal-to-noise ratio in our data set.
Conclusion
We proposed a modeling strategy that could provide insights to clinical QA professionals to help them mitigate key clinical quality issues (e.g., safety, consent, data integrity) in a more sustained data-driven way, thus turning the traditional reactive approach to a more proactive monitoring and alerting approach. Also, we are calling for cross-sponsors collaborations and data sharing to improve and further validate the use of statistical models in clinical QA.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference20 articles.
1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E26(R2) guideline for good clinical practices. 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 10 Dec 2019.
2. Li H, Hawlk S, Hanna K, Klein G, Petteway S. Developing and implementing a comprehensive clinical QA audit program. Qual Assur J. 2007;11:128–37.
3. Food and Drug Administration. Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. 2013. https://www.fda.gov/downloads/Drugs/Guidances/UCM269919.pdf. Accessed 10 Dec 2019.
4. Hurley C, Sinnott C, Clarke M, Kearney P, Racine E, Eustace J, et al. Perceived barriers and facilitators to risk based monitoring in academic-led clinical trials: a mixed methods study. Trials. 2017;18:423.
5. Medicine and Healthcare products Regulatory Agency. GCP inspection metrics report. 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/706356/GCP_INSPECTIONS_METRICS_2016-2017__final_11-05-18_.pdf. Accessed 10 Dec 2019.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献